The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York 80+ peptides are fda approved. most people aren't using any of them. bpc 157, tb 500, ipamorelin none completed phase 3 trials. the feb 2026 reclassification to category 1 restored compounding access for 14 The Food and Drug Administration will hold a meeting this summer to consider easing restrictions on more than a half dozen peptide injections, a group of unapproved therapies that have become popular CJC 1295 2026 Review: Mechanism, Uses, Safety & FDA Status